Zobrazeno 1 - 10 of 23 pro vyhledávání: '"Maria Rovithi"'
1
Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
Autor: Rita Ruijter, Godefridus J. Peters, Richard J. Honeywell, Sophie L. Gerritse, Jens Voortman, Albert J. ten Tije, Maria Rovithi, Henk M.W. Verheul, Mariette Labots
Publikováno v: Journal of Clinical Oncology, 37(5), 411-418. American Society of Clinical Oncology
Journal of Clinical Oncology, 37, 411-418
Rovithi, M, Gerritse, S L, Honeywell, R J, Ten Tije, A J, Ruijter, R, Peters, G J, Voortman, J, Labots, M & Verheul, H M W 2019, ' Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors ', Journal of Clinical Oncology, vol. 37, no. 5, pp. 411-418 . https://doi.org/10.1200/JCO.18.00725
Journal of Clinical Oncology, 37, 5, pp. 411-418
PURPOSE Dose and schedule optimization of treatment with tyrosine kinase inhibitors is of utmost importance. On the basis of preclinical data, a phase I clinical trial of once weekly or once every 2 weeks administration of high-dose sunitinib in pati
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dabe6886be85589407c3620adb559393
https://research.vumc.nl/en/publications/46a188f6-b99a-42d6-9082-9fd43f728670
Zobrazit plný text záznamu
2
Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
Autor: Egbert F. Smit, Elisa Giovannetti, Richard J. Honeywell, Ietje Kathmann, Henk M.W. Verheul, Carmelo Tibaldi, Maria Rovithi, Godefridus J. Peters
Publikováno v: Cancers
Volume 12
Issue 11
Honeywell, R J, Kathmann, I, Giovannetti, E, Tibaldi, C, Smit, E F, Rovithi, M N, Verheul, H M W & Peters, G J 2020, ' Epithelial transfer of the tyrosine kinase inhibitors erlotinib, gefitinib, afatinib, crizotinib, sorafenib, sunitinib, and dasatinib: Implications for clinical resistance ', Cancers, vol. 12, no. 11, 3322, pp. 1-18 . https://doi.org/10.3390/cancers12113322
Cancers, 12(11):3322, 1-18. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 12
Cancers, 12, 11
Cancers, Vol 12, Iss 3322, p 3322 (2020)
Cancers, 12(11). MDPI
Background: tyrosine kinase inhibitors (TKIs) inhibit phosphorylation of signaling proteins. TKIs often show large variations in the clinic due to poor pharmacology, possibly leading to resistance. We compared gut absorption of inhibitors of epiderma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71099a2b197c5089f44fbc4739b7926a
https://doi.org/10.3390/cancers12113322
Zobrazit plný text záznamu
3
Taste Alterations During Treatment With Protein Kinase Inhibitors: A Pilot Study
Autor: Anne van der Werf, Marian A. E. de van der Schueren, Sayed M.S. Hashemi, Mariette Labots, Maria Rovithi, Henk M.W. Verheul, Jacqueline A E Langius
Publikováno v: van der Werf, A, de van der Schueren, M A E, Rovithi, M, Labots, M, Hashemi, S M S, Langius, J A E & Verheul, H M W 2018, ' Taste Alterations During Treatment With Protein Kinase Inhibitors : A Pilot Study ', Journal of Pain and Symptom Management, vol. 56, no. 4, pp. e1-e4 . https://doi.org/10.1016/j.jpainsymman.2018.06.016
Journal of Pain and Symptom Management, 56(4), e1-e4. Elsevier Inc.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09be8b8f4491b81efbaf7d3506833243
https://pubmed.ncbi.nlm.nih.gov/30025935
Zobrazit plný text záznamu
4
Insight in taste alterations during treatment with protein kinase inhibitors
Autor: A. van der Werf, H. M. W. Verheul, J.A.E. Langius, Maria Rovithi, M.A.E. de van der Schueren
Publikováno v: van der Werf, A, Rovithi, M, Langius, J A E, de van der Schueren, M A E & Verheul, H M W 2017, ' Insight in taste alterations during treatment with protein kinase inhibitors ', European Journal of Cancer, vol. 86, pp. 125-134 . https://doi.org/10.1016/j.ejca.2017.09.006
The role of Protein Kinase Inhibitors (PKI) in the treatment of various types of cancer is increasingly prominent. Their clinical application is accompanied by the development of side effects, among which patient-reported taste alterations. These alt
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b19814bcb75548e83f37e0fbf509026e
https://pubmed.ncbi.nlm.nih.gov/28987769
Zobrazit plný text záznamu
5
Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity
Autor: Maria Rovithi, Henk M.W. Verheul
Publikováno v: Angiogenesis, 20(3), 287-289. Springer Netherlands
Angiogenesis
Rovithi, M & Verheul, H M W 2017, ' Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity ', Angiogenesis, vol. 20, no. 3, pp. 287-289 . https://doi.org/10.1007/s10456-017-9555-8
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e069aafb398ea11b51f59832940fae52
https://research.vumc.nl/en/publications/dbb95125-7e7a-4229-be6b-113f807e11dd
Zobrazit plný text záznamu
6
Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells
Autor: Maria Rovithi, Arjan W. Griffioen, Elisa Giovannetti, Thomas Wurdinger, Amir Avan, Niccola Funel, Henk M.W. Verheul, Leticia G. Leon, Valentina E. Gomez
Publikováno v: Scientific Reports, 7:44686. Nature Publishing Group
Rovithi, M, Avan, A, Funel, N, Leon, L G, Gomez, V E, Wurdinger, T, Griffioen, A W, Verheul, H M W & Giovannetti, E 2017, ' Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells : A platform for drug testing ', Scientific Reports, vol. 7, 44686 . https://doi.org/10.1038/srep44686
Scientific Reports
The aim of the present study was to develop chick-embryo chorioallantoic membrane (CAM) bioluminescent tumor models employing low passage cell cultures obtained from primary pancreatic ductal adenocarcinoma (PDAC) cells. Primary PDAC cells transduced
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37dc111c7bfd37157ccaae15309ddc5e
https://doi.org/10.1038/srep44686
Zobrazit plný text záznamu
7
Abstract C079: Effect of food on the pharmacokinetics of high dose intermittent sunitinib in patients with advanced solid tumors
Autor: Nielka P. van Erp, Mikkjal Skardhamar, Maria Rovithi, Angela Colbers, Sophie L. Gerritse, Olaf J.L. Loosveld, Mariette Labots, Henk M.W. Verheul
Publikováno v: Molecular Cancer Therapeutics. 18:C079-C079
Background: Optimization of the clinical use of multi-targeting tyrosine kinase inhibitors (TKIs), as sunitinib, is needed to fully exploit their potential antitumor activity. Sunitinib was developed to inhibit angiogenesis-related kinases, but at co
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a8cdd5678c59f9f429358872570afe9
https://doi.org/10.1158/1535-7163.targ-19-c079
Zobrazit plný text záznamu
8
A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group
Autor: Maria Rovithi, Sofia Agelaki, Dora Hatzidaki, Emmanouil Kontopodis, Vassilis Georgoulias, Nikolaos Vardakis, Ioannis Varthalitis, Nikolaos Kentepozidis, Stylianos Giassas, Nikolaos Pantazopoulos
Publikováno v: Journal of Chemotherapy. 25:49-55
Frequent administration of low doses of cytotoxic drugs (metronomic chemotherapy) has been suggested to suppress tumour growth possibly by inhibiting angiogenesis. We evaluated a metronomic regimen of oral vinorelbine in pre-treated patients with adv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f724b07adcd33fb00f04f5d7a3fb1f2
https://doi.org/10.1179/1973947812y.0000000050
Zobrazit plný text záznamu
9
Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer
Autor: Egbert F. Smit, Joline S.W. Lind, Thang V. Pham, Henk M.W. Verheul, Jaco C. Knol, Johannes Voortman, Connie R. Jimenez, Maria Rovithi
Publikováno v: Rovithi, M, Lind, J S W, Pham, T V, Voortman, J, Knol, J C, Verheul, H M W, Smit, E F & Jimenez, C R 2016, ' Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer ', Proteomics. Clinical applications, vol. 10, no. 7, pp. 743-749 . https://doi.org/10.1002/prca.201600025
Proteomics. Clinical applications, 10(7), 743-749. Wiley-VCH Verlag
Purpose We validated a previously reported proteomic signature, associated with treatment outcome, in an independent cohort of patients with non-small cell lung cancer (NSCLC). A novel peptide signature was developed to predict toxicity. Experimental
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d800222b6ff43386def585c9893fe13
https://research.vumc.nl/en/publications/c4181802-411f-46d1-bf5b-9bceeae4ec58
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje